EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Best Practices in Physiologically Based Pharmacokinetic ( PBPK ) Modeling

Marylore Chenel, Andre Dallmann, Ibrahim Ince, Michaela Meyer, Jan-Frederik Schlender, Donato Teutonico, Erik Sjögren

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70295 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Marylore Chenel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmetheus AB, Uppsala, Sweden. Hauptthemen laut MEDLINE: Models, Biological, Pharmacokinetics, Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic cornerstone of model‐informed drug development (MIDD), providing evidence for regulatory decisions. PBPK models integrate physiological and pharmacological data and have been applied across a plethora of contexts of use, including assessing drug–drug interactions (DDIs), optimizing dosing for special populations (e.g., pediatrics and those with organ impairment), and supporting clinical study waivers. However, despite the established history of PBPK modeling, a significant gap persists between the quality of submitted PBPK analyses and regulatory expectations. Recent reviews by the European Medicines Agency (EMA) and other regulatory bodies indicate that many PBPK models are not deemed adequately qualified for their intended application. This discrepancy highlights the need for consolidated guidance on model development, evaluation, and application, particularly to harmonize terminology and expectations with the ICH M15 guideline. To address this challenge, this paper provides comprehensive best‐practice guidance for the development, verification, validation, and applicability assessment of PBPK models. We delineate strategies for defining explicit technical criteria to ensure models are appropriately qualified and demonstrably fit‐for‐purpose for a specific context of use. This guidance aims to enhance the quality, consistency, and regulatory acceptance of PBPK analyses, thereby strengthening the reliability of MIDD evidence supporting drug development and approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalPharmacokineticsDrug DevelopmentHumansDrug InteractionsPharmaceutical Preparations

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Pharmetheus AB, Uppsala, Sweden.
  • Bayer HealthCare SAS, Regulatory Affairs France, Lille, France.
  • Boehringer Ingelheim Pharma GmbH & co. KG, Ingelheim, Germany.
  • Bayer AG, Model-Informed Drug Development, Wuppertal, Germany.
  • Biomedical Research, Novartis, Basel, Switzerland.
  • Sanofi, Vitry-sur-Seine, France.

Zitieren

APA

Chenel, M., Dallmann, A., Ince, I., Meyer, M., Schlender, J. F., Teutonico, D., & Sjögren, E. (2026). Best Practices in Physiologically Based Pharmacokinetic ( PBPK ) Modeling. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70295

Vancouver

Chenel M, Dallmann A, Ince I, Meyer M, Schlender JF, Teutonico D, et al. Best Practices in Physiologically Based Pharmacokinetic ( PBPK ) Modeling. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70295

BibTeX
@article{Chenel2026,
  author = {Chenel, Marylore and Dallmann, Andre and Ince, Ibrahim and Meyer, Michaela and Schlender, Jan-Frederik and Teutonico, Donato and Sjögren, Erik},
  title = {Best Practices in Physiologically Based Pharmacokinetic ( PBPK ) Modeling},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70295}
}
Kostenlos starten →